The European Medicines Agency’s (EMA) policy on interchangeability of biosimilars relates only to the active substance and formulated product, the agency said in a clarifying statement.
Source: Drug Industry Daily
EMA Clarifies Its Policy on Biosimilar Interchangeability
- Post author:PacConAdmin
- Post published:February 8, 2023
- Post category:Drug Industry Daily